首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Immunology Immunotherapy

Cancer Immunology Immunotherapy杂志,由Springer Berlin Heidelberg出版,于1976年创刊,Monthly,出版语言English,ISSN:0340-7004,E-ISSN:1432-0851。

投稿咨询
Cancer Immunology Immunotherapy
Cancer Immunology Immunotherapy
Cancer Immunology Immunotherapy
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.8
CiteScore
9.5
期刊收录
SCI、SCIE

Cancer Immunology Immunotherapy(中文译名:《癌症免疫学免疫治疗》),ISSN:0340-7004,EISSN:1432-0851,是Springer Berlin Heidelberg出版的国际性学术期刊,创刊于1976年,以Monthly形式稳定发行,2026年总发文量约359篇。该刊采用非OA开放访问,学科归属为医学 - 免疫学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.8,2025年期刊CiteScore为9.5,2025年期刊自引率约3.4%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Cancer Immunology Immunotherapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约1月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、GERMANY (FED REP GER)、Japan、Italy、Netherlands、France等为核心发文国家与地区;HELMHOLTZ ASSOCIATIONINSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、FUDAN UNIVERSITY、EBERHARD KARLS UNIVERSITY OF TUBINGEN、HARVARD UNIVERSITY、RUPRECHT KARLS UNIVERSITY HEIDELBERG、UNIVERSITY OF DUISBURG ESSEN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 IMMUNOLOGY 免疫学
2区 2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
3区 3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
3区 3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 40 / 183

78.4

学科:ONCOLOGY SCIE Q1 67 / 333

80

学科:IMMUNOLOGY SCIE Q1 35 / 183

81.15

学科:ONCOLOGY SCIE Q1 66 / 333

80.33

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 42 / 183

77.3

学科:ONCOLOGY SCIE Q1 68 / 328

79.4

学科:IMMUNOLOGY SCIE Q1 39 / 183

78.96

学科:ONCOLOGY SCIE Q1 71 / 328

78.51


中国学者近期发文

1
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort tria

Author:Zhao, Xiaoying; Feng, Wanjing; Geng, Qirong; Huang, Mingzhu; Zhang, Zhe; Chen, Jinsi; Sheng, Xuedan; Zhu, Xiaodong; Guo, Weijian

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04373-4

2
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphom

Author:Wu, Hui; Zhang, Jiaqing; Xu, Li; Xie, Yifan; Pan, Lingli; Zhang, Xinyue; Xia, Yongming; Yang, Fang; Kang, Xiaozhen; Tong, Xiangmin; Wang, Shibing

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04396-x

3
KSR2 functions as a metabolic checkpoint for anti-PD-1 resistance by reprogramming glucose metabolis

Author:Ge, Yuli; Zhou, Qiong; Zhang, Qiangqiang; Hu, Yanyan; Wang, Rui

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04394-z

4
Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cance

Author:Zhang, Haoke; Yu, Chunyan; Du, Wei; Li, Huiyang; Liu, Zihe; Li, Xueying; Yue, Yuhan; Wang, Bo; Wang, Hongmei; Ouyang, Yuqing; Wu, Haixia; Feng, Xiaofan; Yu, Jianchun; Liu, Yaru; Ji, Boyu; Cai, Siyu; Zhang, Hong; Deng, Weimin

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04387-y

5
Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 202

Author:Hou, Jingyi; Mu, Guangyan; Zhang, Zhuo; Xiang, Qian; Cui, Yimin

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04380-5

6
Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitor

Author:Yang, Fan; Long, Yaping; Li, Yao; Bai, Yibing; Liu, Yining; Cheng, Dingyuan; Li, Tao; Lu, Yiheng; Han, Xiao; Hu, Yi

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04364-5

7
Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysi

Author:Hang, Junjie; Wu, Lixia; Xiao, Li; Duan, Qiuhua; Zhao, Han; Huang, Junjie; Guo, Jinfeng; Huang, Yiqing; Zhang, Dapeng; Cheng, Gang; Dong, Xiao; Xue, Peng; Chang, Jianhua

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04382-3

8
Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy respons

Author:Zhao, Hongying; Liu, Wangyang; Xu, Haotian; Wang, Lu; Chen, Zushun; Sun, Yanwu; Wang, Li

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04374-3

9
Immune checkpoint inhibitor-related myocarditis in patients with thymic epithelial tumors: a retrospective cohort analysi

Author:Zeng, Haiyan; Kang, Jin; Pu, Sijia; Dai, Chang; Jiang, Junrong; Chen, Yanlin; Chen, Yuhan; Fu, Lu; Liu, Huiyi; Guo, Mengmeng; Yi, Hong; Chen, Haowei; Zhong, Wenzhao; Xue, Yumei

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04362-7

10
Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cance

Author:Qin, Xuping; Zhong, Haowen; Liu, Meize; Yu, Tiantian; Ma, Rong; Zhou, Ying; Chen, Jingyu; Liu, Fen; Wang, Xiwei; Long, Jianting

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04351-w


在线咨询

Cancer Immunology Immunotherapy

国际简称:CANCER IMMUNOL IMMUN参考译名:癌症免疫学免疫治疗

年发文量:359 CiteScore:9.5 是否预警:否 Gold OA文章占比:87.15% 研究类文章占比:92.20%

杂志社联系方式:SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013

Cancer Immunology Immunotherapy